CNBX Pharmaceuticals Inc. (CNBX) Cash from Financing Activities (2013 - 2026)

CNBX Pharmaceuticals (CNBX) has 13 years of Cash from Financing Activities data on file, last reported at $45000.0 in Q2 2026.

• Quarterly Cash from Financing Activities rose 125.09% year-over-year to $45000.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $150008.0 (up 14.29% YoY) and the FY2025 annual result came in at $160000.0, up 481.56% from the prior year.
• Cash from Financing Activities advanced to $45000.0 in Q2 2026, from $35000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $240000.0 in Q2 2022 to a low of $1259.0 in Q2 2024.
• A 5-year average of $53158.0 and a median of $30008.0 in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 98.06% — and 2025, when it surged 2281.59%.
• Tracing CNBX's Cash from Financing Activities over 5 years: stood at $149858.0 in 2022, then slumped by 83.32% to $24993.0 in 2023, then climbed by 20.03% to $30000.0 in 2024, then jumped by 33.33% to $40000.0 in 2025, then increased by 12.5% to $45000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $45000.0 (Q2 2026), $35000.0 (Q1 2026), and $40000.0 (Q4 2025), per Business Quant data.